Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDEC-114 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IDEC-114 | DRUG | Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions |
Inclusion Criteria: * Signed IRB-approved informed consent * Greater than or equal to 18 years of age * Proof of follicular lymphoma * Progressive disease requiring treatment after at least 1 prior standard therapy * Acceptable hematologic status, liver function, and renal function * Patients of re...
IDEC-114 is an investigational small molecule being studied for the treatment of Non-Hodgkin's Lymphoma. It has been evaluated in Phase 1 clinical trials, but it is not approved by the FDA and remains in clinical development.
IDEC-114 is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. The drug is in Phase 1 clinical development for Non-Hodgkin's Lymphoma.
IDEC-114 is in Phase 1 clinical development. Two Phase 1 trials have been completed, but the drug is still investigational and has not received FDA approval.
IDEC-114 has been studied in two completed Phase 1 trials. NCT00048555 evaluated IDEC-114 in combination with Rituxan in 90 patients, and NCT00575068 evaluated IDEC-114 alone in 42 patients, both for Non-Hodgkin's Lymphoma.
No, IDEC-114 is not the same as Rituxan. IDEC-114 is a separate investigational small molecule being studied for Non-Hodgkin's Lymphoma, while Rituxan is a different drug that was used in combination with IDEC-114 in one clinical trial.